Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 single-arm open-label study of tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma
MOH_2022-09-12_012040Phase 3Completed
- Sponsor
- Incyte
- Start
- Sep 2022
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of tafasitamab and lenalidomide in diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL), sponsored by Incyte. Primary endpoint: Overall response rate. Started Sep 2022; status: completed.
02
Drugs
tafasitamablenalidomide
03
Conditions
diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)
Beyond the preview
Go deeper on MOH_2022-09-12_012040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-09-12_012040.